First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy
Recruiting now · Phase 1
Conditions studied: Non Small Cell Lung Cancer
In brief
The goal of this clinical trial is to investigate the use of \[89Zr\]Zr-DFO-emapalumab as an IFN-γ PET imaging agent to detect lesions and response to therapy among treatment-naïve non-small cell lung cancer (NSCLC) patients. PET scans following the imaging agent will be completed prior to and about 30 days after starting immunotherapy.
Key facts
- Study ID
- NCT06439914
- Run by
- Nerissa T. Viola
- People needed
- 6
- Starts
- 2026-03-09
- Expected to finish
- 2029-06-01
- Last updated by the study team
- 2026-03-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Karmanos Cancer Institute — Detroit, Michigan, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.